Avaí Bio and Austrianova confirm Klotho secretion in encapsulated cells
Avaí Bio and its joint venture partner Austrianova have reported a preclinical manufacturing milestone: genetically modified cells engineered to produce the protein alpha-Klotho can be encapsulated in Austrianova's proprietary Cell-in-a-Box delivery system while retaining viability and continuing to secrete the protein at what the companies describe as high levels into surrounding culture media.
The work was carried out under the banner of Klothonova, a Nevada-incorporated joint venture equally owned by OTCQB-listed Avaí Bio and SG Austria Pte. Ltd, Austrianova's Singapore-based affiliate. The milestone follows earlier confirmation that Avaí Bio's GMP Master Cell Bank had cleared comprehensive adventitious agent and viral testing, allowing a Working Cell Bank to be established from it.
What was demonstrated
The encapsulation results provide the first formal confirmation that cells manufactured and banked under GMP conditions can be loaded into Cell-in-a-Box capsules without losing their biological function. The capsule membrane, according to the release, supports both long-term containment of the cells and effective outward release of the therapeutic protein, two requirements that must be demonstrated before the platform can progress to in vivo work.
Chris Winter, chief executive of Avaí Bio, said the findings "validate a critical component of our development strategy by confirming that the therapeutic cells remain functional within the Cell-in-a-Box capsules and can release the target protein into the surrounding environment."
Walter Gunzburg, chairman and chief scientific officer of Austrianova, said the programme would now advance to capsule expansion and optimisation studies, covering growth characteristics, long-term functionality, and production performance under conditions intended to support future development milestones. No timeline or target animal study was specified.
Market context and regulatory path
Alpha-Klotho has attracted growing scientific interest as a circulating protein associated with kidney function, cardiovascular protection, and the biology of ageing. Its decline with age has been implicated in a range of organ-level pathologies, which is why it has drawn both academic and commercial attention. Several research groups are exploring Klotho supplementation or gene-delivery strategies, though no product has yet reached late-stage clinical testing, and the regulatory pathway for an encapsulated cell therapy secreting a longevity-associated protein remains novel territory.
Cell encapsulation as a drug delivery modality has a longer history in the treatment of metabolic diseases such as Type 1 diabetes, where the goal is to shield transplanted insulin-producing cells from immune rejection while allowing small-molecule exchange. Applying the same logic to a secreted protein like Klotho is mechanistically plausible, but the field has yet to produce an approved product on this chassis. Avaí Bio is a small OTCQB-listed company, and investors should note that the programme remains at an early preclinical manufacturing stage with no in vivo efficacy or safety data disclosed to date.
The next milestones to watch are the capsule optimisation studies referenced by Austrianova, the initiation of any animal studies, and whether the joint venture publishes its secretion data in a peer-reviewed setting. FDA engagement on the regulatory classification of the Cell-in-a-Box platform for this indication will also be a key upstream question given the therapy's hybrid nature as a living-cell delivery system for a systemic protein.